CD8A and neoplasm: Meanwhile, in an osteosarcoma model, TLR9 agonists remodel the immunosuppressive TME by reducing M2-like macrophages and increasing the infiltration of activated CD8+ T cells (101), indicating that TLR signaling can alter cytokine profiles in the TME, thereby influencing APCs, particularly macrophages, and modifying the course of tumor immunity.